129 related articles for article (PubMed ID: 36527350)
1. Androgen Receptor Blockade Using Enzalutamide Suppresses Long Non-Coding RNA ARLNC1 in Prostate Cancer Cells.
Huseynova G; Özgür E; Bilgiç Gazioğlu S; Esin Yörüker E; Gezer U
Cell J; 2022 Dec; 24(12):774-778. PubMed ID: 36527350
[TBL] [Abstract][Full Text] [Related]
2. Investigation of lncRNA H19 in prostate cancer cells and secreted exosomes upon androgen stimulation or androgen receptor blockage.
Ozgur E; Gezer U
Bratisl Lek Listy; 2020; 121(5):362-365. PubMed ID: 32356434
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression.
Zhang Y; Pitchiaya S; Cieślik M; Niknafs YS; Tien JC; Hosono Y; Iyer MK; Yazdani S; Subramaniam S; Shukla SK; Jiang X; Wang L; Liu TY; Uhl M; Gawronski AR; Qiao Y; Xiao L; Dhanasekaran SM; Juckette KM; Kunju LP; Cao X; Patel U; Batish M; Shukla GC; Paulsen MT; Ljungman M; Jiang H; Mehra R; Backofen R; Sahinalp CS; Freier SM; Watt AT; Guo S; Wei JT; Feng FY; Malik R; Chinnaiyan AM
Nat Genet; 2018 Jun; 50(6):814-824. PubMed ID: 29808028
[TBL] [Abstract][Full Text] [Related]
4.
Özgür E; Celik AI; Darendeliler E; Gezer U
Anticancer Res; 2017 Jul; 37(7):3631-3637. PubMed ID: 28668854
[TBL] [Abstract][Full Text] [Related]
5. Role of Testosterone Levels on the Combinatorial Effect of
Pillai P; Pooleri GK; Nair SV
Integr Cancer Ther; 2021; 20():1534735421996824. PubMed ID: 33615860
[TBL] [Abstract][Full Text] [Related]
6. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
[TBL] [Abstract][Full Text] [Related]
7. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
8. CA916798 affects growth and metastasis of androgen-dependent prostate cancer cells.
He J; Lan X; Duan HL; Luo H; Zhou XD
Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4477-4487. PubMed ID: 30058677
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.
Waltering KK; Helenius MA; Sahu B; Manni V; Linja MJ; Jänne OA; Visakorpi T
Cancer Res; 2009 Oct; 69(20):8141-9. PubMed ID: 19808968
[TBL] [Abstract][Full Text] [Related]
10. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.
Guerrero J; Alfaro IE; Gómez F; Protter AA; Bernales S
Prostate; 2013 Sep; 73(12):1291-305. PubMed ID: 23765603
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and Evaluation of
Antunes IF; Dost RJ; Hoving HD; van Waarde A; Dierckx RAJO; Samplonius DF; Helfrich W; Elsinga PH; de Vries EFJ; de Jong IJ
J Nucl Med; 2021 Aug; 62(8):1140-1145. PubMed ID: 33517325
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
13. Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.
Fernandez EV; Reece KM; Ley AM; Troutman SM; Sissung TM; Price DK; Chau CH; Figg WD
Mol Pharmacol; 2015 Jun; 87(6):1006-12. PubMed ID: 25829060
[TBL] [Abstract][Full Text] [Related]
14. PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling.
Ferreira LB; Palumbo A; de Mello KD; Sternberg C; Caetano MS; de Oliveira FL; Neves AF; Nasciutti LE; Goulart LR; Gimba ER
BMC Cancer; 2012 Nov; 12():507. PubMed ID: 23130941
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line.
Mizokami A; Gotoh A; Yamada H; Keller ET; Matsumoto T
J Urol; 2000 Sep; 164(3 Pt 1):800-5. PubMed ID: 10953159
[TBL] [Abstract][Full Text] [Related]
16. Growth inhibition of androgen-responsive prostate cancer cells with brefeldin A targeting cell cycle and androgen receptor.
Rajamahanty S; Alonzo C; Aynehchi S; Choudhury M; Konno S
J Biomed Sci; 2010 Jan; 17(1):5. PubMed ID: 20102617
[TBL] [Abstract][Full Text] [Related]
17. Antagonistic action of a synthetic androgen ligand mediated by chromatin remodeling in a human prostate cancer cell line.
Sawada T; Kanemoto Y; Amano R; Hayakawa A; Kurokawa T; Mori J; Kato S
Biochem Biophys Res Commun; 2022 Jul; 612():110-118. PubMed ID: 35523048
[TBL] [Abstract][Full Text] [Related]
18. Aspalathus linearis suppresses cell survival and proliferation of enzalutamide-resistant prostate cancer cells via inhibition of c-Myc and stability of androgen receptor.
Wang BJ; Huang SH; Kao CL; Muller CJF; Wang YP; Chang KH; Wen HC; Yeh CC; Shih LJ; Kao YH; Huang SP; Li CY; Chuu CP
PLoS One; 2022; 17(7):e0270803. PubMed ID: 35776912
[TBL] [Abstract][Full Text] [Related]
19. Androgen regulation of aldehyde dehydrogenase 1A3 (ALDH1A3) in the androgen-responsive human prostate cancer cell line LNCaP.
Trasino SE; Harrison EH; Wang TT
Exp Biol Med (Maywood); 2007 Jun; 232(6):762-71. PubMed ID: 17526768
[TBL] [Abstract][Full Text] [Related]
20. Prostate androgen-regulated gene: a novel potential target for androgen-independent prostate cancer therapy.
Xu XF; Zhou SW; Zhang X; Ye ZQ; Zhang JH; Ma X; Zheng T; Li HZ
Asian J Androl; 2006 Jul; 8(4):455-62. PubMed ID: 16763722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
